Literature DB >> 20145083

In vitro fungicidal activities of echinocandins against Candida metapsilosis, C. orthopsilosis, and C. parapsilosis evaluated by time-kill studies.

Emilia Cantón1, Ana Espinel-Ingroff, Javier Pemán, Lucas del Castillo.   

Abstract

Anidulafungin, micafungin, and caspofungin in vitro activities against Candida metapsilosis, C. orthopsilosis, and C. parapsilosis were evaluated by MICs and time-kill methods. All echinocandins showed lower MICs (mean MICs, 0.05 to 0.71 mg/liter) and the highest killing rates (-0.06 to -0.05 CFU/ml/h) for C. metapsilosis and C. orthopsilosis rather than for C. parapsilosis (mean MICs, 0.59 to 1.68 mg/liter). Micafungin and anidulafungin killing rates were greater than those determined for caspofungin. None of the echinocandins had fungicidal activity against C. parapsilosis.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20145083      PMCID： PMC2863676          DOI： 10.1128/AAC.01538-09

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  18 in total

1.  Comparison of killing activity of caspofungin against Candida parapsilosis, Candida orthopsilosis and Candida metapsilosis.

Authors:  I Varga; G Sóczó; G Kardos; A Borbély; Zs Szabó; A Kemény-Beke; L Majoros
Journal:  J Antimicrob Chemother       Date:  2008-09-28       Impact factor: 5.790

2.  In vitro activity of micafungin (FK-463) against Candida spp.: microdilution, time-kill, and postantifungal-effect studies.

Authors:  Erika J Ernst; Ellen E Roling; C Rosemarie Petzold; Douglas J Keele; Michael E Klepser
Journal:  Antimicrob Agents Chemother       Date:  2002-12       Impact factor: 5.191

3.  Strain characterization of Candida parapsilosis fungemia by molecular typing methods.

Authors:  R M Zancopé-Oliveira; M J James; A P Derossi; J L Sampaio; M M Muniz; R K Li; A S Nascimento; J M Peralta; E Reiss
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2000-07       Impact factor: 3.267

4.  Geographic distribution and antifungal susceptibility of the newly described species Candida orthopsilosis and Candida metapsilosis in comparison to the closely related species Candida parapsilosis.

Authors:  Shawn R Lockhart; Shawn A Messer; Michael A Pfaller; Daniel J Diekema
Journal:  J Clin Microbiol       Date:  2008-06-18       Impact factor: 5.948

5.  Identification of pathogenic yeast species by polymerase chain reaction amplification of the RPS0 gene intron fragment.

Authors:  J M García Martínez; E Valentín Gómez; J Pemán; E Cantón; M Gómez García; L del Castillo Agudo
Journal:  J Appl Microbiol       Date:  2009-10-20       Impact factor: 3.772

6.  Prevalence, distribution, and antifungal susceptibility profiles of Candida parapsilosis, C. orthopsilosis, and C. metapsilosis in a tertiary care hospital.

Authors:  Ana P Silva; Isabel M Miranda; Carmen Lisboa; Cidália Pina-Vaz; Acácio G Rodrigues
Journal:  J Clin Microbiol       Date:  2009-06-03       Impact factor: 5.948

7.  In vitro activity of seven systemically active antifungal agents against a large global collection of rare Candida species as determined by CLSI broth microdilution methods.

Authors:  D J Diekema; S A Messer; L B Boyken; R J Hollis; J Kroeger; S Tendolkar; M A Pfaller
Journal:  J Clin Microbiol       Date:  2009-08-26       Impact factor: 5.948

8.  In vitro activities of echinocandins against Candida krusei determined by three methods: MIC and minimal fungicidal concentration measurements and time-kill studies.

Authors:  Emilia Cantón; Javier Pemán; Amparo Valentín; Ana Espinel-Ingroff; Miguel Gobernado
Journal:  Antimicrob Agents Chemother       Date:  2009-04-20       Impact factor: 5.191

9.  A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility.

Authors:  Guillermo Garcia-Effron; Santosh K Katiyar; Steven Park; Thomas D Edlind; David S Perlin
Journal:  Antimicrob Agents Chemother       Date:  2008-04-28       Impact factor: 5.191

10.  Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America.

Authors:  Peter G Pappas; Carol A Kauffman; David Andes; Daniel K Benjamin; Thierry F Calandra; John E Edwards; Scott G Filler; John F Fisher; Bart-Jan Kullberg; Luis Ostrosky-Zeichner; Annette C Reboli; John H Rex; Thomas J Walsh; Jack D Sobel
Journal:  Clin Infect Dis       Date:  2009-03-01       Impact factor: 9.079
View more
  25 in total

1.  Prospective multicenter study of the epidemiology, molecular identification, and antifungal susceptibility of Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis isolated from patients with candidemia.

Authors:  Emilia Cantón; Javier Pemán; Guillermo Quindós; Elena Eraso; Ilargi Miranda-Zapico; María Álvarez; Paloma Merino; Isolina Campos-Herrero; Francesc Marco; Elia Gomez G de la Pedrosa; Genoveva Yagüe; Remedios Guna; Carmen Rubio; Consuelo Miranda; Carmen Pazos; David Velasco
Journal:  Antimicrob Agents Chemother       Date:  2011-09-19       Impact factor: 5.191

2.  Microsatellite genotyping clarified conspicuous accumulation of Candida parapsilosis at a cardiothoracic surgery intensive care unit.

Authors:  Magda Diab-Elschahawi; Christina Forstner; Ferry Hagen; Jacques F Meis; Andrea M Lassnig; Elisabeth Presterl; Corné H W Klaassen
Journal:  J Clin Microbiol       Date:  2012-08-08       Impact factor: 5.948

3.  Assessment of two new molecular methods for identification of Candida parapsilosis sensu lato species.

Authors:  Guillermo Garcia-Effron; Emilia Canton; Javier Pemán; Amanda Dilger; Eva Romá; David S Perlin
Journal:  J Clin Microbiol       Date:  2011-07-27       Impact factor: 5.948

4.  Dose escalation studies with caspofungin against Candida glabrata.

Authors:  Marianna Domán; Renátó Kovács; David S Perlin; Gábor Kardos; Rudolf Gesztelyi; Béla Juhász; Aliz Bozó; László Majoros
Journal:  J Med Microbiol       Date:  2015-06-30       Impact factor: 2.472

5.  Prevalence and distribution profiles of Candida parapsilosis, Candida orthopsilosis and Candida metapsilosis responsible for superficial candidiasis in a Chinese university hospital.

Authors:  Xiaobo Feng; Bo Ling; Guimei Yang; Xia Yu; Daming Ren; Zhirong Yao
Journal:  Mycopathologia       Date:  2011-11-19       Impact factor: 2.574

Review 6.  Candida parapsilosis: from Genes to the Bedside.

Authors:  Renáta Tóth; Jozef Nosek; Héctor M Mora-Montes; Toni Gabaldon; Joseph M Bliss; Joshua D Nosanchuk; Siobhán A Turner; Geraldine Butler; Csaba Vágvölgyi; Attila Gácser
Journal:  Clin Microbiol Rev       Date:  2019-02-27       Impact factor: 26.132

7.  Anidulafungin in treatment of experimental invasive infection by Candida parapsilosis: in vitro activity, (1-->3)-beta-D-glucan and mannan serum levels, histopathological findings, and in vivo efficacy.

Authors:  Valentina Salas; F Javier Pastor; Enrique Calvo; Emilio Mayayo; Guillermo Quindós; Alfonso J Carrillo; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2011-08-15       Impact factor: 5.191

Review 8.  Antifungal lock therapy.

Authors:  Carla J Walraven; Samuel A Lee
Journal:  Antimicrob Agents Chemother       Date:  2012-10-15       Impact factor: 5.191

9.  Epidemiology and echinocandin susceptibility of Candida parapsilosis sensu lato species isolated from bloodstream infections at a Spanish university hospital.

Authors:  Guillermo Garcia-Effron; Emilia Canton; Javier Pemán; Amanda Dilger; Eva Romá; David S Perlin
Journal:  J Antimicrob Chemother       Date:  2012-08-06       Impact factor: 5.790

10.  Anidulafungin versus caspofungin in a mouse model of candidiasis caused by anidulafungin-susceptible Candida parapsilosis isolates with different degrees of caspofungin susceptibility.

Authors:  Dimitra Dimopoulou; Georgios Hamilos; Maria Tzardi; Russell E Lewis; George Samonis; Dimitrios P Kontoyiannis
Journal:  Antimicrob Agents Chemother       Date:  2013-10-21       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.